



Annual Report

2011

Luminex[®]

*At Luminex, we know that uncertainty is the antithesis of scientific and medical success. **Whether in a lab, at a hospital or in the field, progress is made when questions are answered.** We help shine a light into the darkest areas of biology, to find out what people need to know most.*





Letter to Shareholders

2011 was a year of significant accomplishments for your company. Luminex grew revenue 30% and achieved record operating margins while strengthening our investment in research and development to drive long-term shareholder value. Every day, we apply our passion for innovative solutions that transform the way laboratories around the world diagnose patients and answer leading edge life-science questions. This focus on innovation has positioned Luminex as a market pioneer and first-mover, particularly in multiplex assays for targeted molecular and protein based testing, contributing to our ability to generate long term revenue growth above 20%.

Our customers need real solutions, especially given the economic turmoil over the past several years. They are constantly searching for ways to achieve more with fewer resources. Luminex has continued to thrive because our products and technologies enable laboratories to save valuable time, sample, and other resources. Whether diagnosing a respiratory virus or researching antibody responses, we help our customers find answers more efficiently so that together we can advance healthcare and science around the world.

Our inspiration starts with our customers. We constantly strive to improve and advance the ways that we serve them.

“I am inspired to work with such a committed and motivated team that continually challenges the status quo and sets new standards for our industry. I am exceptionally proud of our accomplishments to date and look forward to a strong future ahead.”

From innovative new products to technical support, customers demand and expect solutions that help them achieve their goals – making their work easier, faster and more cost-effective. Through our unique approach Luminex sets a new standard for the way testing is performed. No longer are customers limited to generating only one answer from one test. With xMAP® Technology, customers can perform up to 500 bioassays at one time, using one sample to achieve multiple results.

We achieved several milestones in 2011. We expanded our product portfolio through the launch of our FDA cleared xTAG® RVP-FAST, our CE marked xTAG Gastrointestinal Pathogen Panel,

and with our acquisition of EraGen® Biosciences, which expanded both our product menu and technology platform to include MultiCode®, a flexible PCR based chemistry. In addition, we are gaining momentum with the newest addition to our instrument product line, MAGPIX®, and expanding our global reach to laboratories of all sizes. Although we are proud of our accomplishments, we are even more excited for the future.

Looking ahead we see incredible opportunity but recognize that we need to continue to execute well. We are investing in your company's future by strengthening our presence around the globe and expanding our product lines. In 2012 I am particularly excited about our prospects in the

biothreat market, the increased adoption of MAGPIX, and the progress we are making on our assay portfolio with the xTAG Gastrointestinal Pathogen Panel and NeoPlex4® newborn screening assay. We are committed to executing on these and other initiatives to drive long-term growth and shareholder value.


I am pleased to work alongside our talented and dedicated employees. We share a common passion not just to spur innovation and advance science, but also to support our communities through participation in causes such as Be The Match® which raises awareness of the need for bone marrow donors. Activities like these allow us not only to fulfill our mission to improve the quality of life for patients around the world, but to play a crucial role in saving lives. Making a difference is what drives us and sets us apart and why I am grateful to lead this organization. Thank you for your continued confidence, and I look forward to a bright future for Luminex.

Sincerely,

Patrick J. Balthrop, Sr.
Chief Executive Officer and President

Five Year Cumulative Total Return*

(among Luminex Corporation, the NASDAQ Composite Index and the NASDAQ Biotechnology Index)



*\$100 invested on 12/31/06 in stock or index, including reinvestment of dividends. Fiscal year ending December 31.

PERFORMANCE HIGHLIGHTS

LMNX STOCK GAINED

▲16
PERCENT

2011 PERFORMANCE VS.
NASDAQ LOSS OF 2%

SYSTEM PLACEMENTS

978
INSTRUMENTS


8,678 SYSTEMS SHIPPED
THROUGH 2011

EARNINGS


\$0.34
PER SHARE

DILUTED EPS INCREASED
183 PERCENT OVER 2010

Revenue Mix



Operating Margin



HIGH-MARGIN ITEMS

▲ 41
PERCENT

2011 INCREASE IN CONSUMABLES,
ROYALTIES, ASSAYS

OPERATING MARGIN

▲ 498
BASIS PTS.

2011 INCREASE OF
\$12.6 MILLION

OPERATING CASH FLOW


▲ 58
PERCENT

OPERATING CASH FLOW OF
\$38.3 MILLION

Consumable Revenue

(\$ in millions)


30% CAGR 2007-2011



Royalty Revenue

(\$ in millions)


30% CAGR 2007-2011



Assay Revenue


(\$ in millions)

44% CAGR 2007-2011



Total Revenue (\$ in millions)

25.2% CAGR 2007-2011



TOTAL REVENUE UP

▲30
PERCENT

TOTAL REVENUE REACHED
\$184.3 MILLION

ASSAY REVENUE UP

▲51
PERCENT

2011 ASSAY REVENUE OF
\$48.7 MILLION

CONSUMABLE REVENUE UP

▲38
PERCENT

2011 REVENUES TOALED
\$55.5 MILLION

Innovation

Innovation is at the heart of everything we do. Our expanding product pipeline is driven by our unwavering commitment to research and development and our strong intellectual property portfolio, which now includes hundreds of issued and pending patents. In addition, our partners continue to invest in our technology and together **we provide a significant assay portfolio for research, biotreat and clinical diagnostics, including over 60 FDA cleared products.**

In May, we received CE marking for our new xTAG Gastrointestinal Pathogen Panel (GPP). In a single test, this innovative assay identifies up to 95 percent of the pathogens that cause infectious diarrhea, in less than 5 hours.

Our proprietary technology allows for faster turn-around time and simultaneous testing on a single sample, thus enabling laboratories to utilize their time and resources more efficiently. **The ability to provide accurate and timely identification of causative pathogens leads to improved patient outcomes and reduced healthcare costs.**


Achieving definitive differential diagnosis of diarrheal disease and infectious

gastroenteritis has traditionally required multiple tests, and these results have not been available for several days. This has frustrated physicians, increased the cost of healthcare and many patients have been at a higher risk of complications. High risk patients such as young children, the elderly, and immunocompromised individuals suffering from these diseases can substantially benefit from rapid diagnosis and faster therapeutic intervention.

The importance of comprehensive testing for gastrointestinal pathogens was highlighted during the European *E. coli* outbreak in June 2011. According to WHO 908 people

were sickened with hemolytic uremic syndrome (HUS), a type of kidney failure that is associated with Shiga toxin-producing *E. coli*, or STEC, infections. There were 50 deaths associated with HUS and thousands of non-HUS cases were identified as people flooded hospitals to determine if they were sick with the highly virulent *E. coli* strain.

"Prior to the release in May 2011 of xTAG GPP, we did not have a test that would allow us to rapidly detect a comprehensive array of disease-causing pathogens for infectious gastroenteritis," said PD Dr. Frauke Mattner, of Kliniken der Stadt, Institute of Pathology and Institute for Hygiene. "The ability of



Infectious gastroenteritis strikes more than two billion people globally each year and is a leading cause of child morbidity and mortality worldwide.

Source: World Health Organization

A year of achievement

Growth

February 2011

Luminex Corporation Ranked One of the 25 Fastest-Growing Technology Companies in America by Forbes for Third Consecutive Year

Recognition

April 2011

Medical Design Excellence Award. Luminex Corporation Wins Prestigious Medical Design Excellence Award for its innovative MAGPIX instrument

"We are committed to building technologies that provide innovative healthcare solutions to people around the world and xTAG® GPP is a great example of our efforts."

xTAG GPP to detect not only several different types of *E. coli*, but also the presence of the Stx-2 gene, a key marker of this more severe STEC strain, allowed rapid identification of patients suffering from an infection of this outbreak strain. This innovative technology was an important advancement for the laboratory and an invaluable tool in the management of the crisis."

Our gastrointestinal pathogen panel is only one example of our innovative approach.

Our xTAG Respiratory Viral Panel (RVP) also allows simultaneous testing of multiple viral pathogens and provides similar benefits for laboratories, patients, and the healthcare system. Additionally, rapid, accurate detection of the causative pathogen helps to reduce overuse of antibiotics which continues to be a growing concern.

With our technology and revolutionary products, Luminex is setting a new standard of care for clinical testing. Our passion is to be on the leading edge of diagnostic innovation, to deliver significant advancements over current methods through improved quality, more laboratory efficiency, better patient care and lower overall cost.

SEVANA YAGHOUBIAN, M.Sc.
**DIRECTOR, ADVANCED
TECHNOLOGY GROUP**
**LUMINEX
CORPORATION**



Innovation

May 2011

Luminex receives CE Mark for new xTAG Gastrointestinal Pathogen Panel which simultaneously detects up to 95% of gastrointestinal infections in under five hours

Growth

2011 was a successful year for Luminex, highlighted by strong financial performance and growth across our systems, consumables, royalties and assays. **For the third consecutive year, Forbes named Luminex one of the 25 fastest growing technology companies in America.**

We continue to expand our instrument footprint with over 8,600 multiplexing analyzers shipped to date. **Our newest instrument, MAGPIX, is an important advancement in our goal to create multiplexing solutions for a wide range of applications, geographies, and laboratories of all sizes.** MAGPIX received CE IVD mark in Europe in January 2011, and was awarded a prestigious Medical Design Excellence Award in the category of In Vitro Diagnostics. This innovative system can quickly detect and measure proteins or nucleic acids in a variety of sample types by simultaneously performing up to 50 tests per sample, significantly reducing the amount of sample, consumables, and labor required compared to competing systems.

In June 2011 we expanded access to MAGPIX through a global sales and distribution agreement



“MAGPIX represents a unique platform through which Life Technologies can make its cutting-edge antibody content accessible for a broad range of protein quantitation needs in basic and clinical research.”

Peter Dansky, President of Molecular and Cell Biology at Life Technologies

with Life Technologies Corporation. This partnership, along with our partnership with EMD Millipore, will help accelerate science and improve the efficiency of disease-related research around the world. Together with our partners we will provide customers with broad access to this innovative instrument as well as an extensive assay portfolio.

In addition to partnerships, Luminex is committed to building and growing our market share via organic investment and through strategic acquisitions. **In July 2011, we received FDA clearance for xTAG RVP FAST. This new addition to Luminex's RVP**

product portfolio brings additional testing options to clinical laboratories looking for a front line assay targeting eight essential respiratory pathogens and delivering up to 96 patient results in a few hours.

RVP FAST features a streamlined and scalable workflow which is important in effectively managing fluctuating patient volumes and seasonal spikes typically associated with influenza-like illnesses.

In June 2011 Luminex acquired EraGen Biosciences, Inc. further expanding our molecular diagnostic and infectious disease capabilities.

Public Health

June 2011

xTAG Gastrointestinal Pathogen Panel from Luminex aids German hospital in management of European *E. coli* crisis

Partnership

June 2011

Luminex and Life Technologies sign agreement for global distribution of the award-winning MAGPIX® Multiplexing Instrument

"Trialling GPP clinically in our lab, we have consistently seen a faster turnaround of results and a 3-fold increase in the number of enteric pathogens detected. I believe GPP could set a new diagnostic standard of practice and be a valuable tool in aiding the infection control management of gastroenteritis in a healthcare setting."

The purchase of EraGen Biosciences provides Luminex with access to a highly complementary portfolio of molecular diagnostic assays based on an innovative and proprietary chemistry called **MultiCode**. This unique chemistry is a flexible platform for both real-time polymerase chain reaction (PCR) and multiplex PCR-based applications. This acquisition is expected to provide growth with additional resources for sales, support, and assay development. **With EraGen—now called Luminex Madison—a part of the team, we are further strengthening our leadership position and expanding our presence within the molecular diagnostic market.**

Our customers are our highest priority, whether they are clinical laboratory professionals, academic and biopharma researchers or biothreat experts. The solutions we develop are designed to make it easier, more cost-effective and efficient to produce results that will help patients and advance healthcare and basic science research.

At Luminex we are always mindful of what is important to our customer, and we will continue to innovate and strive to deliver the best solutions to meet their needs.

DR. EUGENE HALLIGAN
INFECTION MOLECULAR
DEVELOPMENT
MANAGER
GSTS PATHOLOGY,
ST. THOMAS'
HOSPITAL, LONDON
UNITED KINGDOM



New Possibilities

June 2011

Luminex acquires EraGen Biosciences, a private MDx company with proprietary chemistry and focus on infectious and genetic diseases for \$34M in cash

Looking Forward

We are very excited about our future. We believe that continued demand for our pioneering technologies and additional opportunities for strategic growth in new markets and new countries will strengthen our market leadership position worldwide. **We are committed to applying our passion for innovation to advance healthcare and research worldwide, and to provide solutions that answer today's clinical and life-science questions.**

Innovation drives growth and we are committed to delivering new solutions to meet the needs of our customers. **In 2012 we plan to introduce a first of its kind multiplex assay in the newborn screening market** building on the relationships established by our important BSD franchise in sample handling. Using a single sample, NeoPlex4 detects and identifies four of the most common analytes required in standard newborn screening testing. Laboratories will be able to generate more results in less time, at lower overall cost, all from a single sample, thereby saving precious sample from the baby.

We continue to make progress with our biothreat programs across multiple projects. **Luminex has been involved with biothreat related activity for some time and we believe the benefits of these investments are approaching fruition.** We are excited about the opportunity for our technology to assist in establishing Luminex as a leader in the biothreat arena.

In addition to expanding our robust pipeline and our biothreat programs, we intend to further develop international markets in 2012.

We are proud to be transforming global healthcare and life-science research through the development, manufacturing, and marketing of innovative proprietary instruments and first-of-their-kind assays that advance standards of care and deliver cost-effective and rapid results to clinicians and researchers around the world. **We extend our sincere thanks to our loyal customers, employees, partners and shareholders who share our vision for the future.** We look forward to keeping you informed on our progress in 2012.



We are proud to be transforming global healthcare and life science research through the development, manufacturing, and marketing of innovative proprietary instruments and first-of-their-kind assays that advance standards of care.

Expansion


July 2011

Luminex receives U.S. FDA clearance for xTAG RVP FAST a new front line Respiratory Viral Panel Test

Community

October 2011

Luminex joins forces with the national marrow donor program - Be The Match



Corporate Officers and Vice Presidents

Patrick J. Balthrop, Sr.
Chief Executive Officer
and President

Russell W. Bradley
Vice President
Business Development
and Strategic Planning

Jeremy Bridge-Cook, Ph.D.
Senior Vice President
Assay Group

Harriss T. Currie
Chief Financial Officer
Vice President
Treasurer

Timothy R. Dehne
Vice President
Systems Research
and Development

Michael F. Pintek
Senior Vice President
Operations

David S. Reiter
Vice President
General Counsel
and Corporate Secretary

Amy L. Altman, Ph.D.
Vice President
Biodefense and Food Safety

Steven Back
Vice President
Manufacturing and
Quality Surveillance

Thomas J. Copa
Vice President
Luminex Life Sciences

Andrew D. Ewing
Vice President
Partner and Operations
Development

Gregory J. Gosch
Vice President
Immunodiagnosics

Scott C. Johnson, Ph.D.
Vice President
Product Development &
Manufacturing

Nancy Krunic, Ph.D.
Vice President
Luminex Molecular
Diagnostics

Darin S. Leigh
Vice President
Commercial Operations

Oliver H. Meek
Vice President
Quality Assurance
and Regulatory Affairs

Board of Directors

G. Walter Loewenbaum, II (1)
Chairman of the Board,
3D Systems Corporation

Patrick J. Balthrop, Sr. (1) (5)
Chief Executive Officer
and President

Robert J. Cresci (3) (4)
Managing Director, Pecks
Management Partners Ltd.
Director, j2 Global
Communications, Inc.

Thomas W. Erickson (1) (3)
Retired Senior Advisor to
New Mountain Capital, LLC
Chairman of the Board, Inmar, Inc.
Director, American Renal
Associates

Fred C. Goad, Jr. (2) (4)
Member, Voyent Partners, Inc.

Jay B. Johnston (2) (5)
Retired Corporate Vice President
for Diagnostic Assays and
Systems, Abbott Laboratories
Chairman of the Board,
QuesTek Innovations, LLC

Jim D. Keever (2)
Member, Voyent Partners, LLC
Director, 3D Systems Corporation
Director, Tyson Foods, Inc.

Kevin M. McNamara (3)
Retired Executive Vice President,
Chief Financial Officer and
Treasurer of HealthSprings, Inc.
Director, Tyson Foods, Inc.

Edward A. Ogunro, Ph.D. (4) (5)
Retired Senior Vice President, R&D
and Medical Affairs
and Chief Scientific Officer,
Hospira, Inc.

Gerard Vaillant (2) (5)
Retired Company Group
Chairman, Johnson & Johnson
Chairman, Safeorthopedics
Acting CEO, Tecan AG
Director, Tecan AG

(1) Member of the Executive
Committee

(2) Member of the
Compensation Committee

(3) Member of the Audit
Committee

(4) Member of the Nominating
and Corporate Governance
Committee

(5) Member of the Strategy and
Development Committee

Independent Registered Public Accountants

Ernst & Young LLP
Austin, Texas

Annual Meeting of Stockholders

The annual meeting of stockholders will be held on Thursday, May 17, 2012, at 10:00 a.m., Central Standard Time, at Luminex's Corporate Headquarters located at 12212 Technology Boulevard, Austin, TX, 78729.

Transfer Agent and Registrar

Mellon Investor Services, LLC
480 Washington Boulevard
Jersey City, New Jersey 07310
1.866.635.6965

Form 10-K/Investor Contact

A copy of the Company's Annual Report on Form 10-K, filed with the Securities and Exchange Commission, may be obtained from the Company at no charge. Requests for the Annual Report on Form 10-K and other investor information should be directed to Investor Relations at the Company's corporate office or www.luminexcorp.com or by e-mail to: investor@luminexcorp.com

Cautionary Note Regarding Forward-Looking Statements

This report contains forward-looking statements (all statements other than those made solely with respect to historical fact) under the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding our future financial position, business strategy, new products, assay sales, budgets, liquidity, cash flows, projected costs, litigation costs, including the costs or impact of any litigation settlements or orders, regulatory approvals or the impact of any laws or regulations applicable to us, and plans and objectives of management for future operations, are subject to known and unknown risks and uncertainties (some of which are beyond the Company's control) that could cause actual results to differ materially and adversely from those anticipated in the forward-looking statements. See the Company's 10-K filing for more detailed disclosure regarding forward-looking statements and associated risks and uncertainties.

Luminex Locations

Global Headquarters

12212 Technology Boulevard
Austin, Texas 78727
United States
512.219.8020

Madison, Wisconsin

918 Deming Way, Suite 201,
Madison, WI 53717
United States
608.662.9000

Canada

439 University Avenue,
Suite 900
Toronto, Ontario M5G 1Y8
Canada
416.593.4323

Europe

Luminex B.V.
Krombraak 15
4906 Oosterhout
The Netherlands
+31.16.240.8333

Japan

Luminex Japan
Corporation Ltd.
Kamiyacho Sankei Bldg 3F
1-7-2 Azabudai
Minato-ku, Tokyo 106-0041
Japan
+81.3.5545.7440

China

Luminex Trading (Shanghai)
Co. Ltd
Unit 6405, Building 6
No. 339 Cai Lun Rd.
Zhangjiang Hi-Tech Park
Pudong District
Shanghai 201203
P. R. China
+86.21.61650809/61650810

Australia

Building 1, 243 Bradman Street
Acacia Ridge
Brisbane, Queensland 4110
Australia
+617.3273.0273

Luminex[®]

www.luminexcorp.com